Cipher Pharmaceuticals Inc has seen a modest uptick in stock performance this week, with no major news impacting its price.
As of today, Cipher Pharmaceuticals Inc (CPH.TO) closed at C$17.07, reflecting a 2.43% increase over the past week. The stock has shown steady performance with a year-to-date gain of 12.95%, despite recent market fluctuations. Investors may want to understand the factors behind this price movement.
Advertisement
Cipher Pharmaceuticals Inc
CPH.TO
CPH.TO
Cipher Pharmaceuticals Inc
WealthAwesomeMarket cap
$346.92M
P/E
8.9x
52W high
$20.56
52W low
$12.48
1W change
-0.36%
Beta
0.41
Analyst Price Targets
Based on analyst covering CPH · as of Sep 23, 2026
Wall Street analysts forecast CPH stock price to rise 42.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$19.45
+42.5% Upside
Previously C$19.95 on Sep 17, 2026
Current Price
C$13.65
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CPH's historical volatility
30-Day Vol
23.8%
Annualized
90-Day Vol
46.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$11.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.72 | C$11.72 – C$13.81 |
| 60 trading days | C$11.98 | C$10.67 – C$13.46 |
| 90 trading days | C$11.29 | C$9.79 – C$13.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Cipher Pharmaceuticals has shown solid financial performance in recent quarters, which likely boosts investor sentiment. However, the lack of recent news suggests that the stock's movement may be driven more by technical factors and broader market trends.
Cipher Pharmaceuticals Reports 25% Increase in Adjusted EBITDA in Q1 2026.
The company's recent financial results highlight a strong performance, with a cash balance of C$6.4 million and a notable year-over-year increase in adjusted EBITDA, indicating operational efficiency.
Bull case
Cipher's recent financial results, including a significant increase in revenue and net income, suggest a solid growth path. Its low P/E ratio compared to industry averages may also present a buying opportunity for value investors.
Bear case
The lack of recent news may create uncertainty among investors. Additionally, the stock's relatively low beta indicates lower volatility, which could limit potential gains in a bullish market. Any negative sentiment in the healthcare sector could also affect Cipher's performance.
Recent Price Action
This week, Cipher Pharmaceuticals Inc (CPH.TO) has seen a 2.43% increase in its stock price, closing at C$17.07. The stock has remained stable with a year-to-date gain of 12.95%, despite a slight decline of 1.98% over the past month. Today's performance reflects a consistent trend, as the company has reported strong financial results in recent quarters.
Catalysts and Company News
Advertisement
There hasn't been any major company news this week that directly impacts Cipher Pharmaceuticals. However, recent headlines indicate that the company reported a 25% increase in adjusted EBITDA for Q1 2026, along with a significant cash balance. These results highlight the company's financial health and may contribute to positive investor sentiment.
Technical Picture
Cipher Pharmaceuticals is currently trading above its 50-day moving average of C$16.57, indicating a bullish trend. The stock's 200-day moving average stands at C$15.90, which is also below the current price, suggesting strong upward momentum. The 52-week range for CPH.TO is between C$12.48 and C$20.56, with the current price at approximately 57% of this range. The stock has a beta of 0.48, indicating lower volatility compared to the broader market, and the current trading volume of 31,499 shares is significantly above the 20-day average volume of 13,607 shares.
Insider Activity
No insider activity has been reported for Cipher Pharmaceuticals this week, which may indicate stability in management and investor confidence in the company's direction.
Price Action Summary
Cipher Pharmaceuticals Inc closed at C$17.07, with no change in price today. The stock has increased by 2.43% over the past week, reflecting solid performance amidst strong financial results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
